BridgeBio(US:BBIO)2026-03-10 18:02Summary of BridgeBio's 2026 Conference Call Company Overview - Company: BridgeBio (NasdaqGS:BBIO) - Event: 2026 Leerink Partners Global Healthcare Conference - Date: March 10, 2026 Key Points TTR Market and Attruby Performance - Patient Growth: Accelerated from approximately 60 patients per week at launch to over 150 patients per week, indicating strong market acceptance [3][5] - Market Dynamics: The growth is attributed to: - Strong clinical data supporting Attruby as the first near-complete stabilizer for TTR [3] - Increased disease awareness and improved diagnosis through AI initiatives [4] - Broader prescriber base, particularly high-volume heart failure clinics [4][5] - Market Share: Achieved over 25% share in treatment-naive patients within a year of launch, with a goal of exceeding 30% [5] - Pricing Stability: Net pricing for Attruby remains stable, with gross-to-net ratios in the 30%-40% range [6][7] European Market and BEYONTTRA - Partnership with Bayer: Successful collaboration for the launch of BEYONTTRA, with over 50% treatment-naive share in Germany due to a single-payer system [9][10] - Future Launches: Upcoming launches planned in Denmark, Spain, Italy, and France, with royalties starting at 30% [11] Combination Therapy and Competitive Landscape - Tafamidis IP Discussion: Potential outcomes for tafamidis patent litigation could impact market dynamics, with expectations of generic entry possibly in the 2030s [12] - Combination Therapy Insights: Current data shows no significant benefits from combination therapies, with a focus on establishing Attruby as the most potent stabilizer [13][14] Pipeline Developments - Depleter Program: BridgeBio is developing an in-house depleter to complement Attruby, targeting the removal of monomers that cause cardiomyopathy [15][16][17] - Achondroplasia Strategy: Infigratinib is positioned as a superior oral treatment option, with a focus on market expansion through patient switches from injections [18][22][23] - Global Launch Plans: International strategy involves a phased approach, starting with Germany, with regulatory filings expected to lag behind U.S. timelines by 3-4 months [27][28] Financial Outlook and Margin Profile - Cost Management: R&D expenses are expected to remain flat, while SG&A expenses will increase due to upcoming launches [39] - Margin Expectations: Anticipated gross margins for new products could reach 70%-80%, with a significant increase in total operating spend as new products launch [50] Additional Insights - Equity Stake in GondolaBio: BridgeBio holds an equity stake in GondolaBio, an early-stage R&D engine, which may be integrated into future strategies [52] This summary encapsulates the critical insights and strategic directions discussed during the conference call, highlighting BridgeBio's growth trajectory, market strategies, and financial outlook.